secwatch.observer — SEC 8-K summary
======================================

Issuer:     Provention Bio, Inc. (—)
CIK:        0001695357
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001493152-23-007347
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi to acquire Provention Bio for $25.00 per share, equity value ~$2.9B
--------------------------------------------------------------------------

- Sanofi to acquire Provention via tender offer at $25.00/share cash; equity value ~$2.9 billion.
- TZIELD (teplizumab) is lead asset, first therapy to delay onset of Stage 3 type 1 diabetes.
- Offer subject to majority tender, HSR clearance, and other customary conditions; no financing condition.
- Provention must pay $100M termination fee; Sanofi must pay $158M reverse termination fee if antitrust fails.
- Executive employment agreements amended to adjust severance multiples and provide tax gross-up (up to $15M aggregate).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/0001493152-23-007347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer